Truist analyst David MacDonald lowered the firm’s price target on CVS Health (CVS) to $60 from $67 and keeps a Buy rating on ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic investments in the new drug applications portfolio.

Zydus Lifesciences announces CVS Caremark agreement and FDA priority review for diabetes and Menkes disease treatments.

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Zydus Lifesciences (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation driven healthcare company announced that it has entered into an agreement with CVS ...

Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.

Shares of CVS Health Corp. CVS inched 0.11% higher to $45.82 Monday, on what proved to be an all-around mixed trading session ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...

All of the commercial prescriptions dispensed at CVS pharmacies will be processed through its CostVantage reimbursement model ...

Aetna, the health, medical and benefits insurance unit of CVS Health, is back in the insurance-linked securities (ILS) market and seeking what could become its largest issuance in the long-standing ...

CVS Health has been named as a Top 25 dividend stock, according the most recent Dividend Channel "DividendRank" report.